RBC Upgrades Guardant Health to Outperform, Cites Growth Catalysts
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
guardant-healthrbc-capital-markets
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
RBC Capital Markets initiated coverage of Guardant Health with an Outperform rating on 12 June 2026. The firm cited a series of near-term catalysts and the company's long-term growth prospects in the multi-billion dollar liquid biopsy market as core reasons for the bullish stance. The upgrade follows Guardant's first quarter 2026 revenue of $169 million, a 22% year-over-year increase.
The last major upgrade from a bulge-bracket firm came in 2025, when JP Morgan raised its price target on Guardant by 30% ahead of its colorectal cancer screening study readout. The current macro backdrop for high-growth healthcare stocks remains challenging, with the iShares Biotechnology ETF (IBB) down 5% year-to-date as of 10 June 2026 against a backdrop of sustained higher interest rates. The catalyst for RBC's positive initiation is the imminent readout of the LUNAR-2 study for colorectal cancer screening, expected in the third quarter of 2026. Positive data here represents a pivotal commercial inflection, potentially unlocking a market exceeding $20 billion in the United States alone.
Guardant's core business of guiding therapy selection for advanced cancer patients continues to demonstrate strong adoption. The company reported over 45,000 clinical tests delivered in Q1 2026, a metric that has grown sequentially for the past eight quarters. This fundamental commercial traction provides a revenue floor while the market awaits binary clinical data. The combination of steady execution in its existing franchise and a near-term, high-stakes catalyst creates a unique window for analyst reassessment, prompting RBC's entry.
Guardant Health's stock closed at $28.45 on 11 June 2026, the day before RBC's upgrade. The company's market capitalization stood at approximately $3.4 billion. RBC's new price target was not disclosed in the initial report, but the upgrade itself implies a projected upside from that baseline. Guardant's trailing twelve-month revenue reached $619 million, yet the firm remains unprofitable on a GAAP basis, reporting a net loss of $479 million over the same period. The company's cash and equivalents totaled $1.1 billion as of 31 March 2026.
A comparison of its growth profile to a key peer, Exact Sciences, reveals divergent valuations. Exact Sciences, with a market cap of $12.8 billion, trades at a price-to-sales multiple of 4.1x based on 2025 revenue. Guardant Health trades at a 5.5x multiple on the same basis, reflecting a premium for its pure-play exposure to liquid biopsy and its upcoming pipeline catalysts. The median analyst price target for Guardant across 25 covering firms was $32.50 prior to RBC's initiation, suggesting a consensus 14% upside potential.
A successful LUNAR-2 readout would directly benefit Guardant's chief competitors in the multi-cancer early detection (MCED) space, including Exact Sciences and Grail, a subsidiary of Illumina (ILMN). Positive data validates the entire liquid biopsy screening thesis, likely lifting the sector. Conversely, a negative result would disproportionately hurt Guardant but could provide a relative advantage to Exact Sciences, whose Cologuard test is already FDA-approved for colorectal cancer screening. Within diagnostics, second-order beneficiaries include companies providing sequencing services, such as Illumina and Pacific Biosciences (PACB), which supply critical tools for liquid biopsy assays.
The primary counter-argument to RBC's bullish view centers on Guardant's sustained cash burn and the intensely competitive landscape. Rival MCED tests from companies like Freenome and Thrive Earlier Detection are advancing, and payer reimbursement for expensive screening tests remains a persistent hurdle. Institutional positioning data from the week ending 7 June 2026 showed a net inflow of $18 million into the iShares Genomics Immunology and Healthcare ETF (IDNA), which holds Guardant, suggesting some early accumulation ahead of the catalyst. Hedge fund activity, measured by 13F filings, indicates a slight increase in aggregate long positions among top holders during Q1 2026.
The immediate catalyst is the LUNAR-2 clinical trial results for colorectal cancer screening, expected by September 2026. Following that, Guardant's second quarter 2026 earnings report, scheduled for early August, will provide an update on commercial test volume growth and cash utilization. A key technical level to monitor is the stock's 200-day moving average, currently at $26.80, which has acted as support. A sustained break above the $30.50 resistance level, last tested in April 2026, would confirm the bullish momentum initiated by the RBC upgrade. The Centers for Medicare & Medicaid Services (CMS) is expected to release its final National Coverage Determination for MCED tests in early 2027, which will dictate long-term reimbursement viability.
An Outperform rating is a relative recommendation, implying the analyst expects the stock to perform better than the broader market or its sector benchmark over a specified period, typically 12-18 months. A Buy rating is often considered an absolute recommendation. For large institutions, an Outperform initiation from a firm like RBC can influence portfolio weighting decisions, potentially driving significant capital allocation into the stock relative to its peers in the healthcare sector.
Guardant Health generates the majority of its revenue from its Guardant360 and GuardantOMNI liquid biopsy tests, which are used by oncologists to identify genomic alterations in advanced cancer patients to guide targeted therapy selection. This precision oncology segment delivered approximately 88% of total revenue in 2025. The company's future growth strategy is heavily dependent on successfully commercializing its LUNAR portfolio for cancer screening in asymptomatic individuals, a much larger addressable market.
The two primary risks are clinical and regulatory. A failure of the LUNAR-2 study to meet its primary endpoints would severely damage the investment thesis and likely cause a sharp de-rating of the stock. Secondly, achieving favorable and broad insurance coverage for a screening test is a prolonged process; any delays or restrictive decisions from Medicare and private payers would impede commercial adoption and revenue growth, extending the company's path to profitability.
RBC's upgrade reflects a calculated bet on Guardant Health's ability to convert near-term clinical data into long-term commercial dominance in liquid biopsy.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.